BriaCell Therapeutics Corp.

BCTX Nasdaq SEC CIK 1610820
Follow BriaCell Therapeutics Corp. Weekly email: filings, results, news

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7.2M −16.9% vs same quarter last year
EPS, diluted −$0.99 +94% vs same quarter last year
Operating cash flow −$7M +2% vs same quarter last year
Operating income −$7.6M −20.4% vs same quarter last year
Net income by quarter
−$1.2M
−$5.8M
−$6.3M
−$6.1M
−$8.1M
−$8.2M
−$7.2M
−$7.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$30M−$20M−$10M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$26.3M
FY24−$4.8M
FY23−$20.3M
FY22−$26.8M
FY21−$13.8M
FY20-

News

No stories filed under BriaCell Therapeutics Corp. yet - coverage appears here as the news feed clusters it.